Prognostic importance of atrial fibrillation in heart failure according to time elapsed since diagnosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 585 KB, PDF-dokument

OriginalsprogEngelsk
TidsskriftHeart Rhythm O2
Vol/bind3
Udgave nummer4
Sider (fra-til)430-432
ISSN2666-5018
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Dr Schwartz was funded by NIH StARR Grant 1R38HL143584 . Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine .

Funding Information:
Dr Schwartz was funded by NIH StARR Grant 1R38HL143584. Dr Ramachandran was supported in part by the Evans Medical Foundation and the Jay and Louis Coffman Endowment from the Department of Medicine, Boston University School of Medicine. Dr Schou has received lecture fees from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk that are unrelated to the present work. Dr Køber reports lecture fees from Novartis, BMS, and AstraZeneca that are unrelated to the present work. Dr Torp-Pedersen has received study funding from Bayer and Novo Nordisk that is unrelated to the present work. All other authors declare that they have no conflicts of interest. All authors attest they meet the current ICMJE criteria for authorship. Consent was waived due ot the use of de-identified data. This study was exempted from ethical board approval, as the data from the registry used in this study were de-identified.

ID: 319157561